Trial site
Instytut Zdrowia Dr Boczarska-Jedynak Sp. z o.o. S.K.
Oswiecim, 32-600, PolandEU-13 widening countryNot linked to an institution yet
- 16running trials
- 20closed trials
The trials here
What the 36 trials at this site are about, from their registry records.
- Phase
- Phase 320 trials
- Phase 212 trials
- Phase 42 trials
- Phase 1/21 trial
- Phase 2/31 trial
- Status
- Completed20 trials
- Active, not recruiting9 trials
- Recruiting6 trials
- Not yet recruiting1 trial
- Lead sponsor
- H. Lundbeck A/S5 trials
- Ipsen5 trials
- Hoffmann-La Roche4 trials
- Pfizer3 trials
- AbbVie2 trials
- and 14 more
Running trials
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886· Phase 2· Hoffmann-La Roche· Source
Recruiting
Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasticity
2024-517745-14-00· Phase 2· Celgene Corp.· Source
Active, not recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
NCT07018713· Phase 3· Merz Therapeutics GmbH· Source
Active, not recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700· Phase 3· Merz Therapeutics GmbH· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203· Phase 3· Bristol-Myers Squibb· Source
Recruiting
A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults
NCT06937931· Phase 2· Ipsen· Source
Recruiting
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
NCT06976268· Phase 2/3· Biohaven Therapeutics Ltd.· Source
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060· Phase 2· Ipsen· Source
Recruiting
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
NCT05054140· Phase 2· Immunic AG· Source
Recruiting
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172· Phase 3· H. Lundbeck A/S· Source
Recruiting
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675· Phase 3· H. Lundbeck A/S· Source
Recruiting
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
NCT04752774· Phase 1/2· Ipsen· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586023· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999· Phase 3· Hoffmann-La Roche· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease
2024-516966-12-00· Phase 2· Novartis Pharma AG· Source
Completed
A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of iN1011-N17-02 in Patients with Post herpetic Neuralgia(PHN)
2024-518747-38-00· Phase 2· iN Therapeutics Co. Ltd.· Source
Active, not recruiting
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293· Phase 3· AbbVie· Source
Active, not recruiting
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
NCT06706622· Phase 3· H. Lundbeck A/S· Source
Completed
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
NCT06323928· Phase 2· H. Lundbeck A/S· Source
Completed
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
NCT06241313· Phase 3· AbbVie· Source
Completed
A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse
2024-516672-16-00· Phase 3· Ab Science· Source
Active, not recruiting
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
NCT06047444· Phase 3· Ipsen· Source
Active, not recruiting
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
NCT06047457· Phase 3· Ipsen· Source
Completed
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
NCT05798520· Phase 2· Biogen· Source
Completed
An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study)
2022-501850-12-00· Phase 2· Arctic Bioscience AS· Source
Completed
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
NCT05518123· Phase 4· Pfizer· Source
Completed
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
NCT05509400· Phase 4· Pfizer· Source
Completed
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
NCT05189210· Phase 2· GemVax & Kael· Source
Completed
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
NCT05348785· Phase 2· Biogen· Source
Completed
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
NCT05206513· Phase 3· Neurocrine Biosciences· Source
Completed
Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine
NCT04921384· Phase 3· H. Lundbeck A/S· Source
Completed
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
NCT04777396· Phase 3· Novo Nordisk A/S· Source
Completed
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
NCT04777409· Phase 3· Novo Nordisk A/S· Source
Completed
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT04408755· Phase 3· Otsuka Pharmaceutical Development & Commercialization Inc.· Source
Report an error